Masimo to Supplement Merger Proxy Amid Shareholder Lawsuits; Deal Terms Unchanged
MASI sits 42% above its 52-week low of $125.94 on light trading volume (0.4× avg).
Summary
Masimo Corp announced it will voluntarily supplement its definitive proxy statement related to the proposed merger with Danaher. This decision comes in response to multiple shareholder lawsuits and demand letters alleging the initial proxy was incomplete. While the company denies the claims, the supplementation aims to reduce litigation risk and avoid potential delays to the merger. Importantly, the per-share merger consideration and the Board's recommendation to vote for the merger remain unchanged, indicating the core deal structure is unaffected. Traders should monitor the resolution of these legal challenges and the merger's progression, though the company's proactive measures suggest a commitment to closing the transaction.
At the time of this announcement, MASI was trading at $178.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4B. The 52-week trading range was $125.94 to $179.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.